Basilea Pharmaceutica AG
🇬🇧XLON.0QNAUnited KingdomNot reported
Price£68.50-0.60 (-0.87%)
Latest anomalies
Neutral 1 detected in the last 120 days
- High: 2
- Medium: 0
- Low: 0
52-week high: the price is trading close to this level
Asset turnover: a sudden drop below its trailing quarter average
Working capital turnover: a sudden drop below its trailing quarter average
Free with a Finzer account.
Profile
- United Kingdom
Identity
- Exchange
- London Stock Exchange . XLON
- Type
- Stock
- ISIN
- Not reported
- CUSIP
- Not reported
Company
- Employees
- 180
- Headquarters
- Allschwil, United Kingdom
- Website
- https://www.basilea.com
Market
- Shares outstanding
- 10.9M
- Market cap
- £772.5M
Key dates
- Next earnings
- Feb 16, 2027
Highlights
- Market cap
- £772.5M
- EPS LTM
- CHF 5.23
- P/E LTM
- 9.62
- Div yield
- 2.46%
Fundamentals (LTM)
- Revenue
- CHF 216.48M+41.89%up year on year
- Net income
- CHF 72.12M+8,374.27%up year on year
- Gross margin
- 83.64%+0.4%up year on year
- Free cash flow
- CHF 27.41M+460.54%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Basilea Pharmaceutica AG is listed on London Stock Exchange (United Kingdom) under the ticker 0QNA. Its market capitalisation is £772.5M, from 10.9M shares outstanding, as of . Across the 248 trading sessions to the shares traded between £44.73 and £70.40, and the last close of £68.50 sits 93% of the way up that range. The company is headquartered in Allschwil, United Kingdom, and employs about 180 people. This is the London Stock Exchange listing of Basilea Pharmaceutica AG; its primary listing is BSLN on SIX Swiss Exchange.
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), and acute bacterial skin and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold and yeast infections; ceftibuten-ledaborbactam, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe Enterobacteriaceae infections. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.